Employees: 1,733
Size Getein Biotech (603387.SS) is a China Health Care company (Biotechnology) with a market value of $625M, the 3153rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.27 on 18 Nov 2026.
Performance Over six months the shares fell 12.9%, against -22.0% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 7.9% over the last twelve months (peer median +18.6%); the operating margin is 21.3% (peer median -92.0%).
Valuation It trades at 2.6× enterprise value to sales against a peer median of 8.9× (3rd cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.0 points above its cost of capital (5.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.11B | CN¥1.04B | CN¥1.15B | CN¥1.36B | CN¥1.80B |
| Revenue growth | — | -9% | -15% | -25% | — |
| Gross profit | CN¥801M | CN¥659M | CN¥724M | CN¥841M | CN¥1.12B |
| EBITDA | n/a | CN¥293M | CN¥286M | CN¥303M | CN¥556M |
| Net income | CN¥293M | CN¥221M | CN¥224M | CN¥280M | CN¥499M |
| Free cash flow | CN¥355M | CN¥263M | CN¥295M | CN¥84.3M | CN¥305M |
| Capital expenditure | CN¥121M | CN¥151M | CN¥156M | CN¥258M | CN¥217M |
| Total debt | CN¥277M | CN¥482M | CN¥582M | CN¥667M | CN¥591M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603387.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.6% | -15.3% | 9th highest of 21 |
| 6-month return | -12.9% | -22.0% | 8th highest of 20 |
| Distance from 52-week high | -27.6% | -44.8% | 3rd highest of 21 |
| Revenue growth (TTM) | +7.9% | +18.6% | 8th lowest of 18 |
| Operating margin | 21.3% | -92.0% | highest of 18 |
| EV / Sales | 2.6× | 8.9× | 3rd cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -8.9% | 40.1% | least demanding of 5 |
| Growth delivered (Del g) | -1.3% | +24.4% | lowest of 5 |
| Hurdle (Req g minus delivered) | -7.7 pp | +11.7 pp | 2nd least demanding of 5 |
| ROIC minus cost of capital | +8.0 pp | -15.1 pp | highest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | 2.6× | -8.9% | -1.3% |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 4.4× | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 2.8× | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | 48.5× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 1.9× | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | 38.1× | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | 26.8× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | 11.4× | 40.3% | +21.5% |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | 3.2× | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | 14.7× | 44.8% | +14.7% |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | 1,794.8× | n/a | n/a |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 11.0× | 39.8% | +143.5% |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | 105.4× | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 3.4× | 31.9% | +27.2% |
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 2.3× | n/a | n/a |